Pan African Towers,  Nigeria’s leading provider of digital infrastructure, has disclosed the appointment of Oladipo Badru as its new Chief Financial Officer.

The appointment was made at a crucial  moment of the company’s growth, with the recent influx of fresh investments from Development Partners, International and Verod Capital to solidify its position as Nigeria’s largest home grown digital infrastructure provider.

This was reviewed in a company statement released on Sunday.

Badru, taking full responsibility for the company’s financial strategy,  will also play a key role in tracking cash flow and managing investments and capital structures for sustained profitability, the statement noted.

“We are delighted to have Oladipo join the dynamic management team at PAT,” said Azeez Amida, Managing Director and Chief Executive Officer at Pan African Towers.

“We’re confident in Oladipo’s capabilities and look forward to the immense value his experience will bring to PAT’s executive team,” he added.

Oladipo Badru, conveyed his enthusiasm to embark on this new role, stating, “These are very exciting times for the Nigerian Telecommunication industry.

“I look forward to contributing my own quota to Nigeria’s largest homegrown digital infrastructure provider, especially at such an interesting time as this.”

“Nigeria is a huge market, and I am optimistic about the growth we can achieve in collaboration with our clients,” he added.

As maintained by the company statement, Badru brings a robust skill set and “an excellent reputation in financial management from over two decades of experience across diverse industries, where he has led significant transformation and change initiatives.”

Badru,  was the Group Director of Finance at Etisalat Dubai, leading the Finance, Commercial, and Business Development teams, until his appointment.

He earlier served as the Head of Budget and Planning Director of Finance at 9mobile.

However, he was once the General Manager of Financial Reporting and Planning at Helios Towers Nigeria and Pfizer Global Pharmaceuticals.